tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Neuroscientific Biopharmaceuticals Expands Manufacturing and Proves Clinical Efficacy

Story Highlights
Neuroscientific Biopharmaceuticals Expands Manufacturing and Proves Clinical Efficacy

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Neuroscientific Biopharmaceuticals Ltd. ( (AU:NSB) ) just unveiled an update.

Neuroscientific Biopharmaceuticals Ltd. has announced an expansion in manufacturing capacity through a technology transfer with Q-Gen, enhancing its supply chain for stem cell solutions. The company has demonstrated proven clinical efficacy with a 78% overall response rate in a refractory Crohn’s trial, positioning itself strongly in the market for auto-immune disorder treatments.

More about Neuroscientific Biopharmaceuticals Ltd.

Neuroscientific Biopharmaceuticals Ltd. operates in the biopharmaceutical industry, focusing on developing patented stem cell solutions for complex auto-immune disorders and unmet medical needs. The company boasts a robust market cap of approximately $50 million and holds $7.3 million in cash, supported by a strong leadership team with extensive experience in biotechnology and financial services.

Average Trading Volume: 502,544

Technical Sentiment Signal: Buy

Current Market Cap: A$49.89M

For an in-depth examination of NSB stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1